Faron Pharmaceuticals Oy
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| FARN.L | ATORX.ST | HURA | SCLP.L | MDNA.TO | HBP.TO | |
|---|---|---|---|---|---|---|
| Market cap | 65.94M | 6.34M | 138.92M | 123.46M | 39.23M | 62.63M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -4.3 | -0.1 | -3.6 | -47.2 | -1.8 | -7.5 |
| Price/book | 6.8 | 0.2 | 7.6 | -4.9 | 23.6 | 4.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −81.89% | −99.15% | −12.23% | −6.67% | −73.42% | −53.11% |
| Today | −2.99% | −4.72% | +8.46% | 0.00% | +1.19% | −16.33% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All FARN.L news ›Transcript : Faron Pharmaceuticals Oy - Special Call
Presenter SpeechJuho Jalkanen Good afternoon, Europe. Good morning U.S.A. Welcome to the Faron Pharmaceuticals EHA 2026 webcast. My name is Juho Jalkanen, the Chief Executive Officer of Faron... Transcript : Faron Pharmaceuticals Oy -…
Faron Pharmaceuticals Oy: Relative Strength Chart - Stock London S.E.
Compare Faron Pharmaceuticals Oy with the company of your choice via a Relative Strength chart. Real-time FARN price, London S.E. stock exchange Relative Strength Chart Faron Pharmaceuticals Oy Biotechnology & Medical Research All…
Transcript : Faron Pharmaceuticals Oy, H1 2026 Earnings Call, Aug 26, 2026
Presenter SpeechJuho Jalkanen Hello, everyone. Welcome to the Faron Pharmaceuticals half year report webcast. Apologies for the technical issues in the beginning, but I think we're now up and Transcript : Faron Pharmaceuticals Oy, H1 2026…
Faron Pharmaceuticals Oy: Total Return chart (Dividends reinvested) - London S.E. stock market
See the history of Faron Pharmaceuticals Oy, with dividends reinvested. (Total Return chart) FARN Stock market Total Return chart Faron Pharmaceuticals Oy Biotechnology & Medical Research All financial news and data tailored to specific…
Faron Pharmaceuticals Oy Provides Update on Investigator-Initiated Trial Portfolio for Bexmarilimab
Faron Pharmaceuticals Oy provided an update on its portfolio of Investigator-Initiated Trials evaluating bexmarilimab, its wholly owned anti-Clever-1 immunotherapy, in multiple oncology indications....
Faron Pharmaceuticals Oy Announces Encouraging First Overall Survival Data from Frontline Higher-Risk Mds Patients in the Bexmab Phase 1/2 Trial
Faron Pharmaceuticals Oy has conducted its first overall survival data cut from treatment-naïve higher-risk myelodysplastic syndrome patients enrolled in the BEXMAB trial. After a median follow-up... Faron Pharmaceuticals Oy has conducted…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com6
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.